FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2543674533> ?p ?o ?g. }

• W2543674533 endingPage "1752" @default.
• W2543674533 startingPage "1743" @default.
• W2543674533 abstract "NeemAzal® (NA) is a quantified extract from seed kernels of neem, Azadirachta indica A.Juss. (Meliaceae), with a wide spectrum of biological properties, classically ascribed to its limonoid content. NA contains several azadirachtins (A to L), azadirachtin A (AzaA) being its main constituent. AzaA has been shown to inhibit microgamete formation of the rodent malaria parasite Plasmodium berghei, and NA was found to completely inhibit the transmission of Plasmodium berghei to Anopheles stephensi mosquitoes when administered to gametocytemic mice at a corresponding AzaA dose of 50 mg/kg before exposure to mosquitoes. The present study was aimed at i) assessing the pharmacodynamics and duration of action of NA and AzaA against P. berghei exflagellation in systemic circulation in mice and ii) elucidating the transmission blocking activity (TBA) of the main NA constituents. The NA and AzaA pharmacodynamics on exflagellation were assessed through ex vivo exflagellation assays, while TBA of NA constituents was evaluated through in vitro ookinete development assay. Pharmacodynamics experiments: Peripheral blood from P. berghei infected BALB/c mice with circulating mature gametocytes, were treated i.p. with 50 mg/kg and 100 mg/kg pure AzaA and with NeemAzal® (Trifolio-M GmbH) at the corresponding AzaA concentrations. The effect magnitude and duration of action of compounds was estimated by counting exflagellation centers, formed by microgametocytes in process of releasing flagellated gametes, at various time points after treatment in ex vivo exflagellation tests. Ookinete Development Assay: The direct effects of NeemAzal® and AzaA on ookinete development were measured by fluorescence microscopy after incubation of gametocytemic blood with various concentrations of test substances in microplates for 24 h. The exflagellation tests revealed an half-life of NA anti-plasmodial compounds of up to 7 h at a NA dose corresponding to 100 mg/kg equivalent dose of AzaA. The ookinete development assay showed an increased activity of NA against early sporogonic stages compared to that of AzaA. The IC50 value determined for NA was 6.8 µg/ml (CI95: 5.95–7.86), about half of the AzaA IC50 (12.4 µg/ml; CI95: 11.0–14.04). The stronger activity of NA, when compared to AzaA, could not be explained by an additive or synergistic effect by other azadirachtins (B, D and I) present in NA. In fact, the addition of these compounds at 50 µM concentration to AzaA did not evidence any decrease of the IC50 against early sporogonic stages to that obtained with AzaA alone. It is likely that other non-limonoid compounds present in NA may contribute to AzaA activity and enhanced pharmacodynamics against exflagellation both in vitro and in vivo." @default.
• W2543674533 created "2016-11-04" @default.
• W2543674533 creator A5052852656 @default.
• W2543674533 creator A5053204143 @default.
• W2543674533 creator A5061540294 @default.
• W2543674533 creator A5065251140 @default.
• W2543674533 creator A5069965729 @default.
• W2543674533 creator A5073520034 @default.
• W2543674533 creator A5075820883 @default.
• W2543674533 creator A5079156534 @default.
• W2543674533 creator A5080001817 @default.
• W2543674533 creator A5086773287 @default.
• W2543674533 creator A5091296490 @default.
• W2543674533 date "2016-12-01" @default.
• W2543674533 modified "2023-09-30" @default.
• W2543674533 title "In vitro and ex vivo activity of an Azadirachta indica A.Juss. seed kernel extract on early sporogonic development of Plasmodium in comparison with azadirachtin A, its most abundant constituent" @default.
• W2543674533 cites W1498806970 @default.
• W2543674533 cites W1507391401 @default.
• W2543674533 cites W1965665318 @default.
• W2543674533 cites W1976284151 @default.
• W2543674533 cites W1977560610 @default.
• W2543674533 cites W1990296740 @default.
• W2543674533 cites W1995391021 @default.
• W2543674533 cites W2018705349 @default.
• W2543674533 cites W2020236564 @default.
• W2543674533 cites W2020542994 @default.
• W2543674533 cites W2024938615 @default.
• W2543674533 cites W2031653450 @default.
• W2543674533 cites W2031925820 @default.
• W2543674533 cites W2037081223 @default.
• W2543674533 cites W2040713555 @default.
• W2543674533 cites W2065858117 @default.
• W2543674533 cites W2072635941 @default.
• W2543674533 cites W2091370029 @default.
• W2543674533 cites W2110218773 @default.
• W2543674533 cites W2114764193 @default.
• W2543674533 cites W2118348147 @default.
• W2543674533 cites W2122430741 @default.
• W2543674533 cites W2122753628 @default.
• W2543674533 cites W2135125055 @default.
• W2543674533 cites W2142798015 @default.
• W2543674533 cites W2146605792 @default.
• W2543674533 cites W2164191030 @default.
• W2543674533 doi "https://doi.org/10.1016/j.phymed.2016.10.019" @default.
• W2543674533 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27912876" @default.
• W2543674533 hasPublicationYear "2016" @default.
• W2543674533 type Work @default.
• W2543674533 sameAs 2543674533 @default.
• W2543674533 citedByCount "16" @default.
• W2543674533 countsByYear W25436745332017 @default.
• W2543674533 countsByYear W25436745332019 @default.
• W2543674533 countsByYear W25436745332020 @default.
• W2543674533 countsByYear W25436745332022 @default.
• W2543674533 countsByYear W25436745332023 @default.
• W2543674533 crossrefType "journal-article" @default.
• W2543674533 hasAuthorship W2543674533A5052852656 @default.
• W2543674533 hasAuthorship W2543674533A5053204143 @default.
• W2543674533 hasAuthorship W2543674533A5061540294 @default.
• W2543674533 hasAuthorship W2543674533A5065251140 @default.
• W2543674533 hasAuthorship W2543674533A5069965729 @default.
• W2543674533 hasAuthorship W2543674533A5073520034 @default.
• W2543674533 hasAuthorship W2543674533A5075820883 @default.
• W2543674533 hasAuthorship W2543674533A5079156534 @default.
• W2543674533 hasAuthorship W2543674533A5080001817 @default.
• W2543674533 hasAuthorship W2543674533A5086773287 @default.
• W2543674533 hasAuthorship W2543674533A5091296490 @default.
• W2543674533 hasBestOaLocation W25436745332 @default.
• W2543674533 hasConcept C111113717 @default.
• W2543674533 hasConcept C112705442 @default.
• W2543674533 hasConcept C150903083 @default.
• W2543674533 hasConcept C161176658 @default.
• W2543674533 hasConcept C173758957 @default.
• W2543674533 hasConcept C185592680 @default.
• W2543674533 hasConcept C203014093 @default.
• W2543674533 hasConcept C207001950 @default.
• W2543674533 hasConcept C26291073 @default.
• W2543674533 hasConcept C2777237215 @default.
• W2543674533 hasConcept C2777775583 @default.
• W2543674533 hasConcept C2778048844 @default.
• W2543674533 hasConcept C2779955036 @default.
• W2543674533 hasConcept C2780478335 @default.
• W2543674533 hasConcept C2781035296 @default.
• W2543674533 hasConcept C2781131524 @default.
• W2543674533 hasConcept C556039675 @default.
• W2543674533 hasConcept C59822182 @default.
• W2543674533 hasConcept C6557445 @default.
• W2543674533 hasConcept C71924100 @default.
• W2543674533 hasConcept C86803240 @default.
• W2543674533 hasConcept C98274493 @default.
• W2543674533 hasConceptScore W2543674533C111113717 @default.
• W2543674533 hasConceptScore W2543674533C112705442 @default.
• W2543674533 hasConceptScore W2543674533C150903083 @default.
• W2543674533 hasConceptScore W2543674533C161176658 @default.
• W2543674533 hasConceptScore W2543674533C173758957 @default.
• W2543674533 hasConceptScore W2543674533C185592680 @default.
• W2543674533 hasConceptScore W2543674533C203014093 @default.
• W2543674533 hasConceptScore W2543674533C207001950 @default.
• W2543674533 hasConceptScore W2543674533C26291073 @default.

• next